Work

Next-generation antifungal therapeutics: emerging drug targets, precision strategies, and novel treatment modalities

Year: 2026
Type: article
Abstract: Invasive fungal infections (IFIs) remain a major global health threat, particularly among immunocompromised patients. Current antifungals that target ergosterol biosynthesis, cell-wall assembly, and nucleic-acid synthesis are increasingly constrained by toxicity, drug-drug interactions, suboptimal pharmacokinetics, narrow spectra, and rising resistance. This review provides the transition from conventional antifungal agents to a next-generation, precision-oriented therapeutic landscape. In Part I, we expand the antifungal target repertoire beyond classical pathways to include emerging molecular nodes. Part II outlines principles for precision antifungal therapeutics, distinguishing pathogen-specific from broad-spectrum approaches and species-tailored regimens, and integrates rapid diagnostics into companion diagnostic frameworks. Part III surveys advanced therapeutic platforms, encompassing antifungal peptides, antibody-based agents, nucleic acid therapeutics, and engineered probiotic strategies. Part IV highlights drug-delivery innovations, including liposomal and nanoparticle carriers, stimuli-responsive systems, antibody- and ligand-targeted constructs, formulations optimized for biofilm penetration and intracellular delivery, and phage-inspired delivery, with AI-assisted design accelerating formulation optimization. Part V synthesizes combination strategies. Together, these advances define a conceptual framework for precision antifungal medicine that integrates pathogen profiling, host factors, pharmacogenomics, therapeutic drug monitoring, and multi-omics data to individualize therapy, overcome resistance, improve selectivity, and enhance clinical outcomes in IFIs.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236622539
FWCI:
Cites: 345
Cited by:
Related to: 10
Parts: 1